Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fenoterol + oxitropium bromide
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
A combination bronchodilator medication consisting of fenoterol (a beta-2 agonist) and oxitropium bromide (a quaternary anticholinergic compound based on the scopolamine molecule). This combination provides enhanced bronchodilation through complementary mechanisms of action, making it useful in the treatment of respiratory conditions characterized by airway obstruction.
02
Targets
ADRB2 (β2)CHRM3 (M3)
Beyond the preview
Go deeper on fenoterol + oxitropium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fenoterol + oxitropium bromide.